Skip to main content
All lobbying filings

ALLIANCE FOR AGING RESEARCH

Lobbying for ALLIANCE FOR AGING RESEARCH

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $60,000.00 expenses · posted Apr 20, 2026

Official filing document

 Bills named in this filing 5
 Lobbying activity 3
Budget/Appropriations

-FY27 report language for the Food and Drug Administration on antipsychotics black box warning -FY27 report language for the Medicare Program antipsychotics measure -FY27 report language for the Medicare Prescription Payment Plan -FY27 report language for utilization management reform in the Medicare program -FY27 medical research funding -FY27 funding for FDA's Neurology Drug Program

Health Issues

-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants

Medicare/Medicaid

-Implementation of Medicare Part D beneficiary affordability provisions -Nursing home quality measures -Implementation of the Medicare Direct Negotiation Program and its impact on older adults -Utilization management reform in Medicare -Increasing Medication Access for Seniors Act (H.R.6401)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem